Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...